Regal Investment Advisors’s CVS Health CVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $355K | Sell |
4,946
-930
| -16% | -$71.6K | 0.02% | 495 |
|
|
2025
Q4 | $466K | Sell |
5,876
-201
| -3% | -$15.8K | 0.03% | 438 |
|
|
2025
Q3 | $458K | Buy |
6,077
+15
| +0.2% | +$1.03K | 0.03% | 393 |
|
|
2025
Q2 | $418K | Sell |
6,062
-443
| -7% | -$29K | 0.03% | 363 |
|
|
2025
Q1 | $441K | Sell |
6,505
-319
| -5% | -$19.1K | 0.04% | 345 |
|
|
2024
Q4 | $306K | Sell |
6,824
-3,052
| -31% | -$171K | 0.02% | 403 |
|
|
2024
Q3 | $621K | Sell |
9,876
-72,474
| -88% | -$4.23M | 0.04% | 312 |
|
|
2024
Q2 | $4.86M | Buy |
82,350
+11,617
| +16% | +$727K | 0.32% | 89 |
|
|
2024
Q1 | $5.64M | Buy |
70,733
+1,130
| +2% | +$86.3K | 0.39% | 72 |
|
|
2023
Q4 | $5.5M | Buy |
69,603
+10,109
| +17% | +$719K | 0.42% | 68 |
|
|
2023
Q3 | $4.15M | Buy |
59,494
+16,397
| +38% | +$1.16M | 0.35% | 79 |
|
|
2023
Q2 | $2.98M | Buy |
43,097
+6,491
| +18% | +$462K | 0.25% | 109 |
|
|
2023
Q1 | $2.72M | Buy |
36,606
+22,890
| +167% | +$1.92M | 0.24% | 114 |
|
|
2022
Q4 | $1.28M | Buy |
13,716
+224
| +2% | +$21.6K | 0.12% | 162 |
|
|
2022
Q3 | $1.29M | Sell |
13,492
-12,766
| -49% | -$1.26M | 0.14% | 149 |
|
|
2022
Q2 | $2.43M | Sell |
26,258
-734
| -3% | -$71.6K | 0.25% | 107 |
|
|
2022
Q1 | $2.73M | Sell |
26,992
-1,685
| -6% | -$177K | 0.25% | 106 |
|
|
2021
Q4 | $2.96M | Buy |
28,677
+396
| +1% | +$36.6K | 0.26% | 96 |
|
|
2021
Q3 | $2.4M | Buy |
28,281
+7,857
| +38% | +$658K | 0.23% | 112 |
|
|
2021
Q2 | $1.7M | Buy |
+20,424
| New | +$1.67M | 0.17% | 138 |
|
|
2021
Q1 | – | Sell |
-28,602
| Closed | -$1.95M | – | 96 |
|
|
2020
Q4 | $1.95M | Buy |
+28,602
| New | +$1.86M | 0.22% | 116 |
|
|
2020
Q1 | – | Sell |
-36,096
| Closed | -$2.68M | – | 75 |
|
|
2019
Q4 | $2.68M | Sell |
36,096
-6,977
| -16% | -$490K | 0.48% | 58 |
|
|
2019
Q3 | $2.72M | Buy |
43,073
+33,491
| +350% | +$1.98M | 0.53% | 51 |
|
|
2019
Q2 | $522K | Buy |
+9,582
| New | +$516K | 0.1% | 187 |
|
|
2019
Q1 | – | Sell |
-3,529
| Closed | -$231K | – | 365 |
|
|
2018
Q4 | $231K | Buy |
3,529
+660
| +23% | +$49.3K | 0.05% | 285 |
|
|
2018
Q3 | $226K | Buy |
+2,869
| New | +$205K | 0.05% | 282 |
|
|
2015
Q4 | – | Sell |
-1,845
| Closed | -$178K | – | 389 |
|
|
2015
Q3 | $178K | Buy |
1,845
+81
| +5% | +$8.52K | 0.05% | 251 |
|
|
2015
Q2 | $185K | Hold |
1,764
| – | – | 0.05% | 256 |
|
|
2015
Q1 | $182K | Buy |
1,764
+1,560
| +765% | +$158K | 0.05% | 263 |
|
|
2014
Q4 | $20K | Sell |
204
-120
| -37% | -$10.6K | 0.01% | 526 |
|
|
2014
Q3 | $26K | Buy |
324
+84
| +35% | +$6.62K | 0.01% | 515 |
|
|
2014
Q2 | $18K | Hold |
240
| – | – | 0.01% | 566 |
|
|
2014
Q1 | $18K | Hold |
240
| – | – | 0.01% | 530 |
|
|
2013
Q4 | $17K | Hold |
240
| – | – | 0.01% | 487 |
|
|
2013
Q3 | $14K | Hold |
240
| – | – | 0.01% | 531 |
|
|
2013
Q2 | $14K | Buy |
+240
| New | +$13.9K | 0.01% | 520 |
|
Other funds holding CVS
VCM
VPM
Regal Investment Advisors's CVS Position: Q1 2026 in Review
Regal Investment Advisors reduced its CVS Health (CVS) stake by 16% in Q1 2026, selling an estimated $71.6K and leaving 4,946 shares worth $355K. The position accounts for 0.02% of the portfolio, ranked #495.
Regal Investment Advisors first reported a position in CVS in Q2 2013 and has held it in 36 quarters since. The position peaked at $5.64M in Q1 2024. 1,868 funds tracked by Wall St. Rank hold CVS as of Q1 2026.
- Regal Investment Advisors held 4,946 shares of CVS Health worth $355K as of Q1 2026.
- Regal Investment Advisors sold 930 CVS Health shares in Q1 2026, an estimated $71.6K.
- CVS Health made up 0.02% of Regal Investment Advisors's portfolio in Q1 2026, its #495 holding.
- Regal Investment Advisors first reported a position in CVS Health in Q2 2013 and has held it in 36 quarters since.
- Regal Investment Advisors's CVS Health position peaked at $5.64M in Q1 2024.
- 1,868 funds tracked by Wall St. Rank held CVS Health as of Q1 2026.
Based on Regal Investment Advisors's 13F filing for Q1 2026, filed 14 May 2026.